Cangen and Olympus expand lung cancer diagnostics deal:
This article was originally published in Clinica
Executive Summary
Cangen Biotechnologies and Olympus have expanded their collaboration to develop a high-throughput molecular blood test for the early detection of lung cancer. The companies had formed a deal in May 2005 to develop a hybrid DNA- and protein-based lung cancer diagnostic. The expanded collaboration includes funding from Olympus for a prospective clinical study; a trial in Asia is currently recruiting patients. Regarding the test's development, several key DNA markers with 70-80% accuracy have been identified from surgically resected samples. The markers can be used as a hybrid with protein-based markers to improve sensitivity and specificity, Bethesda, Maryland-based Cangen said, adding that it was aiming to gain US approval for the test in around two years.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.